--- title: Are antidepressants effective for PMDD? | Niyora description: Yes. SSRIs (a type of antidepressant) are the first-line treatment for PMDD and work quickly, often within hours to days, which is faster than for other mood url: https://niyora.com/research/papers/antidepressants-in-the-management-of-premenstrual-dysphoric-disorder-evidence-2026/ --- - [Niyora](https://niyora.com/) - [Research](https://niyora.com/research/) - [Library](https://niyora.com/research/library/) - Are antidepressants effective for PMDD? Survey study, 2026 # Are antidepressants effective for PMDD? Yes. SSRIs (a type of antidepressant) are the first-line treatment for PMDD and work quickly, often within hours to days, which is faster than for other mood disorders. Taking them only during the two weeks before the period is an option. Moderate study design Women of reproductive age with PMDD (prevalence 1.8-5.8% of this group) ## What they did Review of research studies published between January 2005 and January 2025 in three medical databases. The reviewers selected 9 studies for final analysis. ## What they found PMDD affects 1.8% to 5.8% of women of reproductive age, with 50% to 90% experiencing subclinical symptoms. More than half of affected women do not receive adequate diagnosis and treatment. SSRIs including sertraline (50-150 mg/day), fluoxetine (10-20 mg/day), escitalopram (10-20 mg/day), and paroxetine (12.5-25 mg/day) are treatments of choice. Unlike other mood disorders, SSRIs in PMDD show rapid onset within hours to days, making intermittent use during the luteal phase feasible. ## What it means for you SSRIs are proven first-line treatment for PMDD with rapid action, but the review shows most women don't get diagnosed or treated properly. Future research needs more standardization in study design and methods to better evaluate PMDD treatments. 1.8-5.8% PMDD prevalence in women of reproductive age 50-90% women with subclinical premenstrual symptoms 9 studies included in review ## About the study Original title Antidepressants in the Management of Premenstrual Dysphoric Disorder: Evidence and Insights Authors I. Mosbah, H. Ghabi, R. Kammoun et al. Journal European Psychiatry Year 2026 Study design Survey study What was tested Selective serotonin reuptake inhibitors (SSRIs) including sertraline, fluoxetine, escitalopram, and paroxetine Open access Yes Read the paper [doi.org/10.1192/j.eurpsy.2026.11771](https://doi.org/10.1192/j.eurpsy.2026.11771) Original abstract Introduction Premenstrual dysphoric disorder (PMDD) was officially recognized in the DSM-5 in 2013. This disorder, which can be particularly debilitating, affects patients’ personal, social, familial, and professional functioning. The prevalence of PMDD ranges from 1.8% to 5.8% among women of reproductive age. Subclinical forms are very common, affecting 50% to 90% of women reporting premenstrual symptoms. Despite this high frequency, more than half of affected women do not receive an adequate diagnosis and remain undertreated. These findings highlight that premenstrual cycle–related symptoms represent one of the most frequent psychiatric and gynecological disorders, yet remain underdiagnosed and insufficiently treated. Objectives The aim of our study was to review the efficacy of antidepressants in PMDD and their prescription modalities. Methods A literature search was conducted between January 2005 and January 2025 in the APA PsycInfo, Scopus, and PubMed databases. After an initial selection based on keywords, full-text screening identified nine studies relevant for the final analysis. Results Antidepressants appear to be the first-line treatment for PMDD, with selective serotonin reuptake inhibitors (SSRIs) showing particularly strong efficacy. These findings support the current etiological hypothesis that natural hormonal fluctuations exert an adverse effect on certain neurotransmitters. SSRIs such as sertraline (50–150 mg/day), fluoxetine (10–20 mg/day), escitalopram (10–20 mg/day), and paroxetine (12.5–25 mg/day) are considered the treatments of choice. Unlike in other mood disorders, SSRIs in PMDD demonstrate a rapid onset of therapeutic action, manifesting within hours to days. This explains why an intermittent regimen (restricted to the luteal phase, i.e., from ovulation to the onset of menstruation) is a feasible option. Conclusions To optimize the evaluation of PMDD treatment efficacy, future studies should be standardized with respect to study design, treatment dosage, and assessment methods. Disclosure of Interest None Declared Reproduced under CC-BY. ## Topics [Premenstrual syndrome (PMS)](https://niyora.com/research/topics/condition-pms/)[Premenstrual dysphoric disorder (PMDD)](https://niyora.com/research/topics/condition-pmdd/)[Low mood and depression](https://niyora.com/research/topics/symptom-depression-mood/)[SSRIs and antidepressants](https://niyora.com/research/topics/treatment-ssri/) Research tells you what helps on average. Niyora helps on the day it hits. Calm down, see it another way, and decide what to say, with a PMS and PMDD app built by a doctor. ## Related studies Systematic review, 2024 What are the best treatments for PMDD and PMS? Review, 2024 What are the most effective treatments for PMDD? Systematic review, 2024 Do SSRI antidepressants help treat PMS and PMDD? Randomised trial, 2023 Does taking sertraline when PMDD symptoms start improve how well women function? Guideline, 2023 How are GnRH agonists used to treat PMDD that doesn't respond to standard medications? Review, 2022 What causes severe PMS and what treatments work? Ask AI about this page Copy prompt ChatGPT ↗ Claude ↗ Perplexity ↗ Google AI Mode ↗ Grok ↗